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Is Breast Cancer Part of the Tumor Spectrum of
Hereditary Nonpolyposis Colorectal Cancer?
To the Editor:
In the January issue of the Journal, Scott et al. (2001)
reported the incidence of various types of cancer in 95
families with hereditary nonpolyposis colorectal cancer
(HNPCC [MIM 120435 and 120436]). The patients in
these families were categorized according to their mis-
match-repair (MMR) profiles. Of these families, 12 were
identified as having an hMSH2 mutation, 22 families
had an hMLH1 mutation, and, in 61 families, no mu-
tation was identified. To our surprise, a remarkably high
incidence of breast cancer was found in the family mem-
bers with HNPCC, particularly in the hMLH1 (stan-
dardized incidence rate [SIR] 14.77 [95% confidence
interval {CI} 6.2–35]) and the mutation-negative (SIR
18.03 [95% CI 12.2–26.7]) groups. No increased inci-
dence was found in the hMSH2 mutation carriers (SIR
2.02 [95% CI 0.3–12.7]). Previous studies reported
much lower incidences of breast cancer in HNPCC. For
instance, Watson and Lynch (1993) identified only 19
cases of breast cancer in 23 families with HNPCC, oc-
curring at a median age of 51 years. The observed:ex-
pected (O:E) ratio in theWatson and Lynch (1993) study
was 0.9. Another recent study of 183 MMR-mutation
carriers by Aarnio et al. (1999) reported an incidence
(SIR) of 1.4 (95% CI 0.4–3.7). These contradictory data
prompted us to evaluate the risk of developing breast
cancer in the families registered at the Dutch HNPCC
registry.
Almost 200 families suspected of HNPCC are currently
known at our registry. A total of 138 families either meet
the “Amsterdam criteria” or harbor a germline mutation
in one of the MMR genes. In 79 families, a germline
mutation has been identified (34 hMLH1, 40 hMSH2,
and 5 hMSH6). Only 4 of 187 proven or putativehMLH1
mutation carriers and 3 of 141 hMSH2mutation carriers
developed breast cancer. The O:E ratio of breast cancer
in hMLH1 mutation carriers was 0.6 (95% CI 0.2–1.5);
in hMSH2mutation carriers, the O:E ratio was 0.6 (95%
CI 0.2–1.7). The mean age at diagnosis was 46 years
(range 32–59 years).
One of these patients, a 32-year-old hMSH2mutation
carrier, underwent periodic examination of the colon
and rectum, endometrium, ovaries, and stomach at the
Department of Gastroenterology and Gynaecology, Lei-
den University Medical Center. Recently, she presented
with an enlarged lymph node (5 cm in diameter) in the
right axilla. On further analysis, a very small tumor in
the upper lateral quadrant of the right breast was dis-
covered. Fine-needle aspiration of the axillary tumor re-
vealed an adenocarcinoma. The patient subsequently un-
derwent a modified radical mastectomy. Histological
examination of the surgical specimen demonstrated
poorly differentiated adenocarcinoma in the breast and
a metastasis in the axilla. Sixteen other lymph nodes
were free of cancer. The estrogen and progesterone re-
ceptors were negative. The tumor exhibited widespread
microsatellite instability (MSI).
In 1996, Risinger et al. performed molecular genetic
studies in five patients with breast cancer from families
with HNPCC. In three of the five tumors, MSI was ob-
served. In one family with a knownmutation, expression
of only the mutant allele was identified in the breast
cancer tissue. In 1999, Boyd et al. described a male pa-
tient, in a large family with HNPCC, affected by breast
and colorectal cancer. This patient had an hMLH1 germ-
line mutation, and the breast tumor exhibited MSI and
reduction to homozygosity for the hMLH1 mutation.
Our study, like most studies reported in the literature,
suggests that the relative risk of developing breast cancer
is not increased in HNPCC. On the other hand, these
studies show that breast tumors in families withHNPCC
may present at an unusually early age, as illustrated by
our patient. In addition, molecular genetic studies reveal
MSI in breast tumors identified in families withHNPCC.
We propose a possible explanation for the contrasting
observations of, on one hand, an unusually early age at
diagnosis of breast cancer and, on the other hand, a
normal (or even decreased) risk of developing breast
cancer. It has generally been accepted that the devel-
opment of breast cancer in the general population takes,
on average, ∼20 years. This suggests that, like non–
mutation carriers in the general population, a carrier of
an MMR gene mutation may develop the first stages of
a tumor at age 40 years. However, because of the defect
in the MMR system, mutations may accumulate in genes
involved in the progression of breast cancer. The accu-
1534 Letters to the Editor
mulation of mutations may lead to acceleration of tumor
development and to presentation of breast cancer at a
much earlier age. The normal lifetime risk of developing
breast cancer in HNPCC patients may indicate that the
MMR defect is not involved in the initiation of breast
cancer.
The answer to the question whether breast cancer is
part of the tumor spectrum of HNPCC should be “no”
if we consider the absence of an increased lifetime risk.
Yet this question should be answered with “yes” if we
take into account the possible role of the MMR defect
in the progression of a breast tumor. Application of the
latter criterion implies that a large variety of tumor types
should in fact be regarded as part of the tumor spectrum
of HNPCC. We believe that decisions as to whether sur-
veillance should be advised for a specific type of cancer
should be based on the age-specific cancer risk and the
availability of sensitive and specific screening tools.
Many cancers that are currently not included in the sur-
veillance programmay develop at an early age in patients
with HNPCC. Therefore, we urge clinicians managing
HNPCC to be especially alert when the patient presents
with unusual symptoms.
H. F. A. VASEN,1 H. MORREAU,2
AND J. W. R. NORTIER1
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Reply to Vasen et al.
To the Editor:
Hereditary nonpolyposis colorectal cancer (HNPCC) is
associated, at least in part, with germline mutations in
genes involved in DNA mismatch repair. Two genes,
termed “hMSH2” and “hMLH1,” account for HNPCC
in ∼60% of families whose symptoms adhere to the
Amsterdam Criteria (Syngal et al. 2000). Three other
genes—hPMS1, hPMS2, and hMSH6—account for an
additional 5%–10%, the exact percentage not being
known at this time. There remains a significant pro-
portion of families, ∼30%, in which HNPCC does not
appear to be accounted for by these genes, suggesting
that additional genes, which may or may not have any-
thing to do with DNA mismatch repair, are involved.
Given that errors in DNA mismatch repair result in the
characteristic signature of microsatellite instability
(MSI), it should be relatively straightforward to deter-
mine whether families whose symptoms adhere to the
Amsterdam Criteria but who do not harbor changes in
known DNAmismatch-repair genes displayMSI. To our
knowledge, little information exists that indicates which
of these two scenarios is most likely.
The letter by Vasen et al. (2001) questions the asso-
ciation between mutations in the DNA mismatch-repair
gene hMLH1 and breast cancer, which we identified in
a report published at the beginning of this year (Scott
et al. 2001). In our report, we presented data that in-
dicated a statistically significant difference between the
likelihood of developing breast cancer in the hMLH1
mutation–positive group and the mutation-negative
group compared with the likelihood in hMSH2 muta-
tion–positive families. One of the reasons we focused on
breast cancer was precisely because there was little or
no agreement as to whether it was part of the disease
spectrum of HNPCC. Furthermore, there were sufficient
anecdotal reports of breast cancer occurring at an earlier
